Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of May 17, 2017. The filing reports a significant clinical milestone regarding the Company's lead drug candidate, NSI-189.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance data.
Material Changes
The primary material event reported is the completion of dosing for the last subject in the Company's multicenter Phase 2 clinical trial evaluating NSI-189 for the treatment of major depressive disorder (MDD).
Outlook and Management Commentary
Management announced the successful completion of the dosing phase for the MDD trial. The filing includes a press release (Exhibit 99.01) detailing this event. No specific financial guidance, risk factors, or contingencies are detailed within the body of this specific 8-K text.
Investor Verification Checklist
- Verify the clinical trial results and data readout timeline for the NSI-189 Phase 2 MDD study.
- Confirm the Company's cash runway and funding status, as this filing contains no financial data.
- Review the attached press release (Exhibit 99.01) for detailed trial design and next steps.
- Monitor for subsequent filings regarding the analysis of the completed trial data.